Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Zafgen (ZFGN) Resumes Trading, Down 29%
March 11, 2019 4:36 PM EDTZafgen (NASDAQ: ZFGN) Resumes Trading, Down 29%
... MoreZafgen (ZFGN) reports Q4 loss per share of 39c, to suspend plans to file IND application for ZGN-1258
March 11, 2019 4:11 PM EDT(Updated - March 11, 2019 4:11 PM EDT)
Zafgen (NASDAQ: ZFGN) reported Q4 EPS of ($0.39), $0.09 better than last year.
Zafgen is also announcing its decision to suspend plans to file an investigational new drug (IND) application for ZGN-1258, the Companys candidate for rare metabolic disorders including Prader-Willi syndrome (PWS), based on a recent, unexpected finding in muscle tissue in four- and six-month long-term rodent toxicology studies. Nonclinical data showed degeneration and other anomalies in rat muscle tissue to different degrees in both vehicle and dose arms of the studies. The effects were... More
